BR112012032766A2 - uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar - Google Patents
uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonarInfo
- Publication number
- BR112012032766A2 BR112012032766A2 BR112012032766A BR112012032766A BR112012032766A2 BR 112012032766 A2 BR112012032766 A2 BR 112012032766A2 BR 112012032766 A BR112012032766 A BR 112012032766A BR 112012032766 A BR112012032766 A BR 112012032766A BR 112012032766 A2 BR112012032766 A2 BR 112012032766A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- pulmonary hypertension
- receptor antagonists
- adenosine receptor
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
uso de antagonistas do receptor de adenosina a~2b ~ para o tratamento da hipertensão pulmonar. esta divulgação refere-se geralmente ao tratamento de pacientes com hipertensão pulmonar, ou os sintomas associados com a mesma, através da administração de uma quantidade terapeuticamente eficaz de um antagonista de receptor a~2b ~ ao paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36028910P | 2010-06-30 | 2010-06-30 | |
PCT/US2011/042379 WO2012003220A1 (en) | 2010-06-30 | 2011-06-29 | Use of a2b adenosine receptor antagonists for treating pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012032766A2 true BR112012032766A2 (pt) | 2019-09-24 |
Family
ID=44343985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012032766A BR112012032766A2 (pt) | 2010-06-30 | 2011-06-29 | uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar |
Country Status (11)
Country | Link |
---|---|
US (1) | US20120003329A1 (pt) |
EP (1) | EP2595630A1 (pt) |
JP (1) | JP2013533882A (pt) |
KR (1) | KR20130088834A (pt) |
CN (1) | CN103237548A (pt) |
AU (1) | AU2011271510A1 (pt) |
BR (1) | BR112012032766A2 (pt) |
CA (1) | CA2802891A1 (pt) |
EA (1) | EA201291274A1 (pt) |
MX (1) | MX2012015112A (pt) |
WO (1) | WO2012003220A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
JP2017048116A (ja) * | 2014-01-10 | 2017-03-09 | 国立研究開発法人国立国際医療研究センター | 肺高血圧症治療薬 |
US20210038510A1 (en) * | 2018-02-08 | 2021-02-11 | Pulmokine, Inc. | Formulations of kinase inhibitors and prostanoids |
SG11202008611UA (en) | 2018-03-05 | 2020-10-29 | Teon Therapeutics Inc | Adenosine receptor antagonists and uses thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US6117878A (en) | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
ES2247356T3 (es) | 2001-06-29 | 2006-03-01 | Cv Therapeutics, Inc. | Derivados de purina com antagonistas del receptor a2b de adenosina. |
UA80258C2 (en) * | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
ATE520694T1 (de) | 2001-11-09 | 2011-09-15 | Gilead Palo Alto Inc | A2b-adenosinrezeptorantagonisten |
US7125993B2 (en) | 2001-11-09 | 2006-10-24 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
DE10303639B4 (de) | 2003-01-30 | 2016-05-25 | Zf Friedrichshafen Ag | Vorrichtung zur Steuerung einer hydraulisch betätigbaren Kupplung eines Automatgetriebes |
US20050101608A1 (en) * | 2003-09-24 | 2005-05-12 | Santel Donald J. | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
NZ589657A (en) * | 2004-10-15 | 2012-06-29 | Gilead Palo Alto Inc | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
CA2612344A1 (en) * | 2005-06-16 | 2006-12-28 | Cv Therapeutics, Inc. | Prodrugs of a2b adenosine receptor antagonists |
ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
HUE025355T2 (en) * | 2006-12-12 | 2016-02-29 | Gilead Sciences Inc | Composition for treating pulmonary hypertension |
CN102015712A (zh) * | 2008-03-26 | 2011-04-13 | 阿德维纳斯治疗私人有限公司 | 作为腺苷受体拮抗剂的杂环化合物 |
-
2011
- 2011-06-29 JP JP2013518651A patent/JP2013533882A/ja active Pending
- 2011-06-29 EA EA201291274A patent/EA201291274A1/ru unknown
- 2011-06-29 CN CN2011800417298A patent/CN103237548A/zh active Pending
- 2011-06-29 WO PCT/US2011/042379 patent/WO2012003220A1/en active Application Filing
- 2011-06-29 EP EP11730524.3A patent/EP2595630A1/en not_active Withdrawn
- 2011-06-29 MX MX2012015112A patent/MX2012015112A/es not_active Application Discontinuation
- 2011-06-29 BR BR112012032766A patent/BR112012032766A2/pt not_active IP Right Cessation
- 2011-06-29 US US13/172,609 patent/US20120003329A1/en not_active Abandoned
- 2011-06-29 AU AU2011271510A patent/AU2011271510A1/en not_active Abandoned
- 2011-06-29 CA CA2802891A patent/CA2802891A1/en not_active Abandoned
- 2011-06-29 KR KR1020137001490A patent/KR20130088834A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2011271510A1 (en) | 2013-01-10 |
CN103237548A (zh) | 2013-08-07 |
EP2595630A1 (en) | 2013-05-29 |
EA201291274A1 (ru) | 2013-12-30 |
CA2802891A1 (en) | 2012-01-05 |
WO2012003220A1 (en) | 2012-01-05 |
US20120003329A1 (en) | 2012-01-05 |
MX2012015112A (es) | 2013-05-28 |
KR20130088834A (ko) | 2013-08-08 |
JP2013533882A (ja) | 2013-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
AR089252A1 (es) | Conjugados de principio activo-ligante (adc) y su uso | |
CY1120159T1 (el) | Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα | |
BR112015031903A8 (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto | |
CL2015002940A1 (es) | Usos terapéuticos de empaglifozina. | |
ECSP088874A (es) | Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual | |
GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
BR112016003229A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica | |
BR112012007102A2 (pt) | compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico | |
BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
BR112015012555A2 (pt) | derivados de benzimidazol como antagonistas de ep4 | |
BR112012028136A2 (pt) | terapia de combinaçao | |
BR112016001114A2 (pt) | membros da família tnf direcionados modificados | |
CL2012000754A1 (es) | Compuestos derivados de benzoxazepina condensadas con pirazolilo o imidazolilo, inhibidores de la actividad de la quinasa pi3; composicion farmaceutica que comprende un compuesto; y su uso en la preparacion de medicamentos para el tratamiento del cancer. | |
CR20120040A (es) | Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades | |
CL2012003745A1 (es) | Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
BR112012020236A2 (pt) | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero | |
BRPI0907230A2 (pt) | composto, prodroga do composto, fármaco, método para tratar ou prevenir uma doença associada com as funções de um receptor de crf, e, uso do composto | |
BR112012032282A2 (pt) | administração transdérmica de memantina | |
BR112012027197A2 (pt) | combinação ou composição farmacêutica, seu uso, kit, e compostos para tratamento de doenças oncológicas e fibróticas | |
BR112012016783A2 (pt) | "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia" | |
EA201400623A1 (ru) | Новые 2h-индазолы в качестве антагонистов рецептора ep | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
BR112012032766A2 (pt) | uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |